Windtree Therapeutics, a Nasdaq-listed biotech firm, has announced plans to purchase up to $700 million in BNB, following the cryptocurrency's recent all-time high. The company is raising $520 million to support this initiative, increasing its previous plan to buy $200 million in BNB. Windtree will partner with Kraken for asset custody and is utilizing a $500 million equity line of credit alongside a $20 million stock purchase agreement to secure funding. BNB, the fifth-largest cryptocurrency with a market cap of $106.9 billion, was recently priced at approximately $769 after peaking at $808. This move aligns with a broader trend of publicly traded companies embracing cryptocurrency assets to enhance their balance sheets. Other companies, like Nano Labs, have similarly announced large BNB purchases, reflecting growing institutional interest in various cryptocurrencies beyond Bitcoin. Windtree's stock has seen significant gains, indicating positive market reactions.

Source 🔗